India's Zydus Lifesciences hits six-month peak on buyback plan
** Shares of Zydus Lifesciences ZYDU.NS rise 5% to a more than six-month high at 986 rupees ** The Indian drugmaker to consider equity share buyback proposal on May 19, 2026 ** Company's unit buys U.S. specialty drugmaker Assertio for $166.4 million ** Average rating of 27 analysts covering the stock is "hold" and median PT is 975 rupees - data compiled by LSEG ** YTD, ZYDU stock up 7.9% (Reporting by Brijesh Patel in Bengaluru) ((Brijesh.Patel1@thomsonreuters.com; Ph no. +91 9590227221;))
Recent news on Zydus Lifesciences
See all newsIndia's Zydus Lifesciences posts lower profit as expenses outpace revenue growth
Brief: Zydus Lifesciences Q2 Consol Net Profit 9.26 Billion Rupees
Brief: Zydus Lifesciences Says Zylidac Bio And Prolific Machines Partner
Brief: Zydus Lifesciences Receives U.S. FDA Approval For Estradiol And Levonorgestrel Transdermal System
Brief: Zydus Lifesciences Says Zydus Sunshine Lifesciences Signs Agreement To Establish A Pharmaceutical Manufacturing Facility In Sri Lanka